Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

JULÄINE™ - Neck Skin Laxity Clinical Investigation

10. november 2026 oppdatert av: Nordberg Medical AB

A Prospective, Multi-Centre, Single-Arm, Open-Label Pivotal Clinical Investigation to Evaluate the Safety and Clinical Performance of JULÄINE™ in Adults With Neck Skin Laxity

This study will assess the safety of JULÄINE™, an injectable filler containing poly-L-lactic acid (PLLA), and whether it can improve loose skin on the neck.

The main question is whether more than 60% of treated participants show an improvement of at least one level on a neck skin laxity scale, 26 weeks after their final treatment. Improvement will be measured by comparing neck skin looseness before and after treatment.

The study plans to enroll adults aged 18 years or older with mild to moderately severe loose neck skin at three sites. All participants will receive the filler during three treatment sessions, approximately four weeks apart.

Participation will last approximately 14 months, including screening, treatment, and follow-up until 52 weeks after the final treatment. Investigators will assess changes using standardised photographs, measurements of skin elasticity, and questionnaires about participants' views of their neck appearance. The study will also monitor adverse events through the final follow-up visit.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

68

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Adults aged 18 years or older with mild to moderate-to-severe neck skin laxity (Grade 2-4 on Neck Laxity Scale).
  • Willing to avoid aesthetic procedures involving the neck and lower face and changes to treatments affecting skin quality during the study.
  • If of childbearing potential, a negative pregnancy test and agreement to use highly effective contraception throughout treatment and for eight weeks afterward.
  • Able to provide written informed consent and comply with study visits, assessments, and post-treatment instructions.

Exclusion Criteria:

  • Pregnancy, breastfeeding, or planned pregnancy or reproductive donation/retrieval procedures during the study or within eight weeks after the final visit.
  • Previous neck surgery or major maxillofacial/cervical surgery; neck injections within 12 months; neck resurfacing or other aesthetic procedures within six months; or planned procedures during the study.
  • Significant neck skin disease, infection, scarring, pigmentation abnormalities, or other conditions interfering with treatment or assessment.
  • Prominent neck muscle bands, excessive facial or neck fat, or anatomy unsuitable for injectable treatment, as assessed by the investigator.
  • Significant thyroid enlargement, uncontrolled thyroid disease, or other unstable endocrine disease.
  • Allergy to device components, coagulation disorders, or anticoagulant/antiplatelet treatment, subject to protocol-defined exceptions.
  • Recent immune-modifying treatment, chemotherapy, or systemic corticosteroids above 10 mg prednisone-equivalent daily; relevant corticosteroid/retinoid use; or treatments affecting collagen production.
  • Hormone replacement therapy or thyroid medication that does not meet protocol-defined stability requirements.
  • Immune deficiency, autoimmune disease, impaired wound healing, or significant malignant, dermatological, or systemic disease.
  • Significant recent or expected weight changes, recent bariatric surgery, ongoing postoperative weight loss, or active weight-loss treatment, subject to protocol-defined exceptions.
  • Any condition preventing valid informed consent or compliance with study requirements.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: JULÄINE™

JULÄINE™, a poly-L-lactic acid (PLLA)-based injectable filler, administered beneath the skin on both sides of the neck during three treatment sessions, approximately four weeks apart.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Participants With Improved Neck Skin Laxity
Tidsramme: Baseline and 26 weeks after the final treatment session

Percentage of participants showing an improvement of at least one grade from baseline on Neck Laxity Scale. The scale ranges from Grade 1 to Grade 5. A decrease in grade indicates improvement.

Baseline and 26 weeks after the final treatment session

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Participants With Improved Neck Skin Laxity at 12 and 52 Weeks
Tidsramme: Baseline and 12 and 52 weeks after the final treatment session

Percentage of participants showing an improvement of at least one grade from baseline on Neck Laxity Scale. The scale ranges from Grade 1 to Grade 5. A decrease in grade indicates improvement.

Baseline and 12 and 52 weeks after the final treatment session
Percentage of Participants With Improved Neck Skin Elasticity
Tidsramme: Baseline and 26 weeks after the final treatment session

Percentage of participants showing an increase of at least 10% from baseline in the Cutometer R2 parameter, a measure of overall skin elasticity. Higher R2 values indicate greater elasticity.

Baseline and 26 weeks after the final treatment session
Investigator-Rated Change in Neck Appearance
Tidsramme: 12, 26, and 52 weeks after the final treatment session

Distribution of investigator ratings on the seven-point Global Aesthetic Improvement Scale, ranging from "very much improved" to "very much worse," based on comparisons of standardised post-treatment and baseline photographs.

12, 26, and 52 weeks after the final treatment session
Change From Baseline in FACE-Q Appraisal of the Neck Score
Tidsramme: Baseline and 12, 26, and 52 weeks after the final treatment session.

Change from baseline in participants' assessment of their neck appearance using the FACE-Q Appraisal of the Neck questionnaire. Raw scores are converted to a score ranging from 0 to 100 using the instrument's scoring algorithm.

Baseline and 12, 26, and 52 weeks after the final treatment session.
Change From Baseline in Neck Skin Firmness and Elasticity Measured by Cutometer
Tidsramme: Baseline and 12, 26, and 52 weeks after the final treatment session.

Change from baseline in four Cutometer parameters: R0 (skin firmness), R2 (gross elasticity), R5 (net elasticity), and R7 (biological elasticity). Lower R0 values indicate firmer skin, while higher R2, R5, and R7 values indicate greater elasticity.

Baseline and 12, 26, and 52 weeks after the final treatment session.
Incidence of Adverse Events and Device Deficiencies
Tidsramme: From the first treatment through 52 weeks after the final treatment session

Number and percentage of participants experiencing adverse events, including device-related events, serious events, and unanticipated serious device-related events. Events will be characterised by type, severity, seriousness, and relationship to the device or injection procedure. Device deficiencies will be summarised separately.

From the first treatment through 52 weeks after the final treatment session

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. juli 2027

Primær fullføring (Antatt)

1. august 2028

Studiet fullført (Antatt)

1. januar 2029

Datoer for studieregistrering

Først innsendt

10. november 2026

Først innsendt som oppfylte QC-kriteriene

10. november 2026

Først lagt ut (Faktiske)

16. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • NB 15-TF-EU-100-38F

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .